Background Intratumor heterogeneity may foster tumor evolution and adaptation and hinder
personalized-medicine strategies that depend on results from single tumor-biopsy samples. …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer medicine.
Here, we review data and technologies that have revealed intra-tumor heterogeneity …

Recent studies have revealed extensive genetic diversity both between and within tumours.
This heterogeneity affects key cancer pathways, driving phenotypic variation, and poses a …

Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …

As tumors grow, they acquire mutations, some of which create neoantigens that influence
the response of patients to immune checkpoint inhibitors. We explored the impact of …

To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

Combination immune checkpoint blockade has demonstrated promising benefit in lung
cancer, but predictors of response to combination therapy are unknown. Using whole-exome …

The interplay between an evolving cancer and a dynamic immune microenvironment remains
unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell lung …

Chromosomal instability is a hallmark of cancer that results from ongoing errors in chromosome
segregation during mitosis. Although chromosomal instability is a major driver of tumour …

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …